EARLY ACS-(TIMI 39) assessed the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST segment elevation acute coronary syndrome.
MAIN RESULTS:
Early versus delayed, provisional eptifibatide in acute coronary syndromes

PRESENTATIONS
TIMI 39 Slides
Morphine-Clopidogrel Interaction & CV Outcomes in Pts with Non-STEMI ACS in EARLY (Furtado AHA 2018)